Cargando…

A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers

Intercellular mechanisms by which the stromal microenvironment contributes to solid tumor progression and targeted therapy resistance remain poorly understood, presenting significant clinical hurdles. PEAK1 (Pseudopodium-Enriched Atypical Kinase One) is an actin cytoskeleton- and focal adhesion-asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamalian, Sarkis, Güth, Robert, Runa, Farhana, Sanchez, Francesca, Vickers, Eric, Agajanian, Megan, Molnar, Justin, Nguyen, Tuan, Gamez, Joshua, Humphries, Jonathan D., Nayak, Anupma, Humphries, Martin J., Tchou, Julia, Zervantonakis, Ioannis K., Kelber, Jonathan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376636/ https://www.ncbi.nlm.nih.gov/pubmed/34239043 http://dx.doi.org/10.1038/s41388-021-01906-2

Ejemplares similares

Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives
por: Runa, Farhana, et al.
Publicado: (2016)

Secretomes from metastatic breast cancer cells, enriched for a prognostically unfavorable LCN2 axis, induce anti-inflammatory MSC actions and a tumor-supportive premetastatic lung
por: Meade, Kayla J., et al.
Publicado: (2019)

INHBA is a prognostic predictor for patients with colon adenocarcinoma
por: Li, Xueying, et al.
Publicado: (2020)

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens
por: Nagaraja, Archana S., et al.
Publicado: (2021)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Fibronectin, DHPS and SLC3A2 Signaling Cooperate to Control Tumor Spheroid Growth, Subcellular eIF5A1/2 Distribution and CDK4/6 Inhibitor Resistance
por: Geller, Cameron, et al.
Publicado: (2023)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

DNA Hypomethylation Is Associated with the Overexpression of INHBA in Upper Tract Urothelial Carcinoma
por: Kao, Chien-Chang, et al.
Publicado: (2022)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Effective implementation of the Accelerate Pheno™ system for positive blood cultures
por: Humphries, Romney, et al.
Publicado: (2019)

INHBA upregulation correlates with poorer prognosis in patients with esophageal squamous cell carcinoma
por: Lyu, Shanshan, et al.
Publicado: (2018)

INHBA is a Prognostic Biomarker and Correlated With Immune Cell Infiltration in Cervical Cancer
por: Zhao, Kaidi, et al.
Publicado: (2022)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Deletion of Snai2 and Snai3 Results in Impaired Physical Development Compounded by Lymphocyte Deficiency
por: Pioli, Peter D., et al.
Publicado: (2013)

Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
por: Park, Youngmok, et al.
Publicado: (2016)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

INHBA is a novel mediator regulating cellular senescence and immune evasion in colorectal cancer
por: Chen, Shuai, et al.
Publicado: (2021)

INHBA promotes the proliferation, migration and invasion of colon cancer cells through the upregulation of VCAN
por: Guo, Jia, et al.
Publicado: (2021)

INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer
por: Liu, Moqing, et al.
Publicado: (2022)

Identification of INHBA as a potential biomarker for gastric cancer through a comprehensive analysis
por: Liu, Fang, et al.
Publicado: (2023)

SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition
por: Sundararajan, Vignesh, et al.
Publicado: (2019)

Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways
por: Zervantonakis, Ioannis K., et al.
Publicado: (2020)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
por: Vogel, Charles, et al.
Publicado: (2010)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells
por: Yallowitz, Alisha, et al.
Publicado: (2018)

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
por: Siddique, Abu Bakar, et al.
Publicado: (2019)

Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
por: Yu, Tosol, et al.
Publicado: (2016)

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
por: Tian, Ziyin, et al.
Publicado: (2022)

Increased Expression of INHBA Is Correlated With Poor Prognosis and High Immune Infiltrating Level in Breast Cancer
por: Yu, Zeying, et al.
Publicado: (2022)

Correlation of INHBA Overexpression with Pathological Features, Antitumor Immune Response and Clinical Prognosis in Cervical Cancer
por: Zeng, Lin, et al.
Publicado: (2023)

An Antiapoptotic Neuroprotective Role for Neuroglobin
por: Brittain, Thomas, et al.
Publicado: (2010)

Antiapoptotic Effects of EGb 761
por: Serrano-García, Norma, et al.
Publicado: (2013)

Antiapoptotic activity of argon and xenon
por: Spaggiari, Sabrina, et al.
Publicado: (2013)

SNAI1 and SNAI2 Are Asymmetrically Expressed at the 2-Cell Stage and Become Segregated to the TE in the Mouse Blastocyst
por: Bell, Christine E., et al.
Publicado: (2009)

Absence of a Major Role for the Snai1 and Snai3 Genes in Regulating Skeletal Muscle Regeneration in Mice
por: Norton, Christine R., et al.
Publicado: (2013)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cadcbmtjaotbhbnjub1lb1nhrj